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“Targeting signs of aging”. It sounds more like 
a punch-line of a TV commercial, than a consequence 
of fundamental science. But as we observed recently, it 
might actually be possible to achieve just that, using a 
prospectively designed FOXO4-p53 interfering peptide 
that targets so-called “senescent” cells [1]. More research 
is needed to fully assess its true translational potential and 
whether it is even safe to remove such cells. However, 
these findings pose a very attractive starting point to 
develop ways to live out our final years in better health.
Aging has often been considered as an integral 
part of life; a form of “noise” that cannot be targeted 
or tampered with. This is in part because for long the 
underlying causes of organismal aging were simply too 
elusive to comprehend, let alone modify. The chronic 
build-up of DNA damage has now evidently been 
established as a major cause for aging, but to counteract 
the genomic damage that has occurred over a lifetime is an 
entirely different challenge altogether [2]. One approach 
to overcome this issue, is to eliminate those cells that 
are too damaged to faithfully perform their duty and to 
replace them by fresh and healthy counterparts. Senescent 
cells are exciting candidates for such an approach. 
Comparable to formation of rust on old equipment, like 
a bicycle (Figure 1), they accumulate during aging and 
especially at sites of pathology. They develop a chronic 
secretory profile that is thought to impair tissue renewal 
and contribute to disease development, for instance by 
keeping neighboring cells “locked” in a permanent state 
of stemness [2]. Senescence can be beneficial in a transient 
setting, but the genetic removal of senescent cells over 
a prolonged period of time was found to be safe and to 
potently extended health- and lifespan of naturally aging 
mice [3]. Thus, senescence is an established cause for 
aging and targeting them is warranted. But can they also 
be eliminated therapeutically? And are such methods then 
safe on their own? And last, but not least, would such 
methods be applicable to not merely delay, but also to 
reverse aging?
Le tour de FOXO. A demanding journey, but one 
with great rewards. 
A first surprise when trying to address these 
questions was that senescent cells recruit a factor called 
FOXO4 to sites of persistent DNA damage, structures 
absent in normal healthy cells [1]. This is intriguing as 
FOXO4 is considered to be the ugly little sister of FOXO1 
and FOXO3, which do play major roles in processes 
ranging from stem cell function, differentiation, tumor 
suppression, and, aging [4]. In senescence, however, 
FOXO4 appears to act as a brake on the apoptosis 
response by sequestering p53. Prospective design of a 
D-Retro-Inversed Cell Penetrating Peptide that perturbs 
this interaction, named FOXO4-DRI, allowed for nuclear 
release of active p53, followed by cell-intrinsic apoptosis 
and selective elimination of the senescent cells. 
Recent work elegantly proved that senescent 
cells are a major cause for the toxic side effects caused 
by multiple independent forms of chemotherapy [5]. 
Excitingly, FOXO4-DRI counteracted senescence caused 
by Doxorubicin and reversed liver toxicity providing 
evidence that therapeutic removal of senescent cells by 
FOXO4-DRI can counteract at least some aspects of 
chemotoxicity. Proceeding from this acute senescence-
induction model, we then focused on fast aging XpdTTD/
TTD mice, which spontaneously develop senescence in 
an accelerated fashion, in parallel with organism-wide 
deterioration. FOXO4-DRI proved to significantly restore 
their health on multiple levels. Though not purposefully 
investigated, it was strikingly apparent that FOXO4-
DRI treated mice regained fur and improved their 
voluntary exploratory behavior compared to PBS treated 
counterparts. In addition, kidney function markedly 
restored. Naturally aged mice showed more biological 
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Figure 1: The aging cycle of life. The analogy compares 
senescent cells in an aged body to rust on a racing bicycle. 
Different strategies can be used to prevent, treat and remove 
rust and aging. WD-40, a corrosion inhibitor, resembles dietary 
restriction and regular exercise to delay rust or aging. When rust 
and aging have already settled, the FOXO4-DRI peptide can act 
as a rust remover by inducing cell death in senescent cells. Last, 
the stimulation of tissue rejuvenation can promote a healthy, 
revitalized tissue that can be compared with the replacement 
of bicycle parts. The combination of these strategies may be 
complimentary in fighting aging and age-related defects.
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noise than the fast aging mice, making these features 
more difficult to address. But at least the effects on renal 
function were clearly prevalent in naturally aged mice. 
Thus, using FOXO4-DRI it indeed appears possible to not 
just delay aging but also reverse at least certain signs of it. 
So, what’s next?
A combination of efforts to best the mountains 
ahead.
Aging is still inevitable. But perhaps it can be 
strongly postponed, or even reversed, when independent 
anti-aging therapies are combined? It remains to be 
determined whether extension of lifespan is possible in 
humans [6], let alone whether this is desirable and then 
to what age? After all, life could at some point not simply 
“complete”? While this might be true for some, nobody 
likes being sick and frail. Imagine the possibilities if we 
would be able to enjoy our time with loved ones, exercise 
and travel more and simply just enjoy life in good health, 
instead of spending it in a retirement home. 
Extending the healthy years of life is now closer than 
ever, but we are still not there yet. While mechanics can 
remove defective parts from an old bicycle, it is far more 
challenging to remove damaged parts from an old body 
(Figure 1). Anti-aging strategies have therefore necessarily 
focused thus far on stalling the inevitable for as long as 
possible by eating less and exercising more. A multitude of 
new diets make it to the mainstream public each year, but 
ironically, people tend to exercise less and gain more and 
more weight. This argues that instead of focusing so much 
on dietary interventions, independent approaches deserve 
to be investigated. Here, we underscored the potential of 
therapeutic elimination of senescent cells, for instance by 
FOXO4-DRI. In addition, exciting developments were 
recently reported in the field of stem cell biology, where 
it was shown that transient expression of the Yamanaka 
stem cell factors can promote tissue rejuvenation [7]. This 
is not yet therapeutically applicable, but most likely this 
will only be a matter of time.
It is no longer merely science-fiction to restore 
healthspan with rationally designed approaches. To 
fully achieve the best possible outcome, it will therefore 
deserve special consideration to combine existing methods 
to delay aging with the recently developed therapies that 
counter senescence and promote tissue rejuvenation. With 
these, we finally have exciting tools to maintain and repair 
the aging cycle of life (Figure 1). Time to gear up and head 
for the finish!
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